Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CibusCBUS +1.59%59 Equity-to-Asset is 0.11 as of Mar. 2026, which is 79% below its 10-year median of 0.53. GuruFocus rates CBUS with a GF Score™ of 59/100 and a GF Value™ of $2.01 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Cibus ranks worse than 84.53% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cibus's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $35.48 Mil. Cibus's Total Assets for the quarter that ended in Mar. 2026 was $324.20 Mil.
Therefore, Cibus's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.11.
The historical rank and industry rank for Cibus's Equity-to-Asset or its related term are showing as below:
CBUS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07 Med: 0.53 Max: 0.83
Current: 0.11
During the past 11 years, the highest Equity to Asset Ratio of Cibus was 0.83. The lowest was 0.07. And the median was 0.53.
CBUS's Equity-to-Asset is ranked worse than 84.53% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs CBUS: 0.11
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cibus Equity-to-Asset Related Terms
Cibus Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cibus's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBUS vs GNLX, ANIX, PEPG: Equity-to-Asset Comparison
For the Biotechnology subindustry, Cibus's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cibus Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cibus's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cibus's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cibus's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cibus (CBUS) has a Equity-to-Asset of 0.11 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cibus and its competitors. This is 79% below median its historical median of 0.53. Over the past decade, Cibus' Equity-to-Asset has ranged from 0.07 to 0.83. According to the industry distribution chart, Cibus ranks #1197 out of 1416 companies in the Biotechnology industry, placing it in the top 84.5%.
Is Cibus' Equity-to-Asset too high?
Cibus' current Equity-to-Asset of 0.11 is 79% below median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.83. The Biotechnology industry median Equity-to-Asset is 0.68. Cibus' value of 0.11 is 83.8% below this industry median. Based on the distribution chart, Cibus ranks #1197 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cibus has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cibus' Equity-to-Asset compare to GNLX and ANIX?
According to the Biotechnology industry distribution chart, Cibus ranks #1197 out of 1416 companies for Equity-to-Asset. This places Cibus in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Cibus' value of 0.11 is 83.8% below this benchmark. Historically, Cibus' own Equity-to-Asset has ranged from 0.07 to 0.83 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 0.68, Cibus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cibus's current Equity-to-Asset of 0.11 is 83.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cibus and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cibus's current Equity-to-Asset is 0.11, which is 79% below median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cibus stock overvalued right now?
Based on GuruFocus' analysis, Cibus (CBUS) is currently considered Fairly Valued. The stock's GF Value™ is $2.01, compared to a current price of $1.92 — trading 4.5% below its estimated fair value. The current Equity-to-Asset is 0.11, which is 79% below median its 10-year median of 0.53 and 83.8% below the Biotechnology industry median of 0.68. Cibus' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cibus (CBUS), the current Equity-to-Asset is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cibus (CBUS) Overvalued in 2026?
Based on GuruFocus' analysis, Cibus stock appears to be undervalued.
The current stock price of $1.92 is trading 4.5% below its estimated GF Value™ of $2.01.
GuruFocus considers Cibus to be Fairly Valued.
Key valuation signals for CBUS:
Equity-to-Asset: 0.11 (79% below median its 10-year median of 0.53)
GF Value™: $2.01 vs. price of $1.92 (4.5% below fair value)
Industry Position: 83.8% below the Biotechnology median (#1197 of 1416)
No single metric tells the full story. See the CBUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
59GF Score
Get the complete analysis for CBUS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBUS has been successfully added to your 
